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Xiaojun Huang, Daihong Liu, Kaiyan Liu, Lanping Xu, Huan Chen, Wei Han,
Yuhong Chen, Yu Wang, Xiaohui ZhangObjective: To evaluate the efficacy and safety of haploidentical (from family member donors) hematopoietic
stem cell transplantation (HSCT) for children. Patients and methods: Fifty-eight children under fourteen
years old with hematological malignancies underwent haploidentical HSCT. Outcomes were analyzed.
Results: Of Fifty-eight patient/donor pairs, seven (12.1%) were mismatched in two HLA loci, twenty
(34.5%) in three loci, and thirty-one (53.4%) in four loci. Follow-ups were performed for a median of 915
(227-1898) days after transplantation. All patients achieved stable engraftments. The cumulative incidence
of acute graft-versus-host disease (GVHD) of grade 2-4 was 54.8%7.6%, and that of grade 3-4 was
11.4%4.8%. The cumulative incidence of chronic GVHD was 45.6%7.8% for total and 19.6%6.5% for exten-
sive. Fourty patients survived with a 3-year probability of leukemia-free survival (LFS) 44.7%13.9%. Eighteen
patients died, five from infection, eight from relapse of leukemia, two from heart failure, two fromGVHD, and
one from lymphoproliferative disorders. Conclusion: The results encourage extending haploidentical
HSCTwithout T-cell depletion treatments to children with an indication for transplantation.
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Despite recent advances in the diagnosis and treat-
ment of childhood hematologic malignancies, there
are several subgroups of children that are at high risk
of failing current chemotherapy regimens and require
allogeneic hematopoietic stem cell transplantation
(HSCT) to cure their disease [1,2]. In this study, we re-
port the results of 58 children under 14 years old that
have no HLA-identical sibling donors and received
HSCT from haploidentical family donors within 6
consecutive years. The toxicity and efficacy of this
transplantation method for children were investigated.PATIENTS AND METHODS
Fifty-eight children under 14 (3-14) years old
with hematologic disorders underwent haploidenticaleking University Institute of Hematology, People’s Hos-
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a median of 780 (180-2738) days after diagnosis.
None of the patients had HLA-identical related or un-
related donors, or a source of stem cells from umbilical
cord blood.Thirty-two patients had acute lymphoblas-
tic leukemia (ALL), 15 patients had acute myeloid leu-
kemia (AML), and 8 patients had chronicmyelogenous
leukemia (CML), 2 hadmyelodisplastic syndromewith
refractory anemia with excess blasts (MDS-RAEB),
and 1 had acute biphenotypic leukemia before HSCT.
Donors were primed with granulocyte-colony
stimulating factor (G-CSF; Filgrastim, Kirin, Japan;
5 mg/kg per day) injected subcutaneously for 5 consec-
utive days. The target mononuclear cell count (MNC)
was 4-6  108 cells/kg recipient weight. On the fourth
day, bone marrow cells were harvested. On the fifth
day, peripheral blood stem cells (PBSC) were col-
lected. 49 patients received G-CSF-primed bone
marrow combined with PBSC at transplantation, 5 pa-
tients received theG-CSF-primed bonemarrow, and 4
patients received PBSC. The day of transplantation
was designated day 0. The conditioning regimen con-
sisted of arabinoside (Ara-C, 4 g/m2/day, i.v.) given on
days –10 and –9; busulfan (Bu, 12 mg/kg, p.o. in 12
doses) given on days –8, –7, and –6; cyclophosphamide
(Cy, 1.8 g/m2/day, i.v.) given on days –5 and –4; Simus-
tine (Me-CCNU, 250mg/kg, i.v.) given on day –3; and91
Figure 1. (a) Cumulative incidence of aGVHD grade 2-4 with HLA dis-
parity after haploidentical HSCT for children. (b) Cumulative incidence
of aGVHD grade 3-4 with HLA disparity after haploidentical HSCT for
children.
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kg/d of the Sangstat, i.v.) given on days –5 through –2.
All transplant recipients received cyclosporine A
(CsA), mycophenolate mofetil (MMF), and short-
term methotrexate (MTX) for graft-versus-host dis-
ease (GVHD) prophylaxis. DNA fingerprinting of
short tandem repeats was used for confirmation of en-
graftment and determination of chimerism. Chromo-
somal fluorescent in situ hybridization (FISH) was
also used to detect chimerism in patients with a donor
of a mismatched gender.
High-risk candidates included patients with acute
leukemia (AL) in the first complete remission (CR1),
those in CR2 with a cytogenetic marker of ‘‘poor
risk,’’ such as the Philadelphia chromosome, those in
complete remission after CR 3, those in nonremission
or in a relapse state before transplantation, and those
with chronic myelogenous leukemia (CML) beyond
the first chronic phase (CP1). All other patients werestratified into a standard-risk group. Thirty children
with AL presented with clinical and biologic features
that indicated a very high risk of relapse with conven-
tional chemotherapy. The primary endpoint of the
study was the overall survival (OS) rate at 3 years
from transplantation. Secondary endpoints included
leukemia-free survival (LFS, defined as survival in con-
tinuous complete remission after transplantation),
nonrelapse mortality (NRM), incidence of relapse,
and incidence and severity of acute and chronic
GVHD (aGVHD, cGVHD). The date of the last fol-
low-up for all surviving patients was August 1, 2008.
All reported P values were based on 2-sided hypothesis
tests. Alpha was set at 0.05. The SPSS-13.0 software
package was used for data analysis.RESULTS
Thirty-six donors weremothers and 17 donors were
fathers of the patients. The other 3 donors were an
uncle, a sister, and a brother; both were haploidentical
according to the familial spectrum of genetics analysis.
Themedian age of the donors was 36 (16-50) years old.
All patients were mismatched at the allele level for
HLA-A, HLA-B, HLA-C, and HLA-DRB1. Thirty-
one (53.4%) patients were mismatched in 4 loci, 20
(34.5%) patients were mismatched in 3 loci, and 7
(12.1%) in 2 loci. The patients were followed up
with a median of 915 (227-1898) days after transplan-
tation. The median numbers of MNC infused at trans-
plantation were 7.9 (1.1-15.4)  108/kg. All patients
achieved stable engraftment and whole donor chime-
rism. The median times of myeloid and platelet recov-
ery were 14 (9-22) days and 21 (8-90) days after
transplantation, respectively. There was no significant
association between the extent of HLA disparity and
the time of myeloid or platelet recovery.
Forty-one patients developed aGVHD, with grade
1 in 15 patients, grade 2 in 21 patients, and grade 4 in 5
patients. The cumulative incidence of aGVHD grade
2-4 was 54.8% 6 7.6%, and that of aGVHD grade
3-4 was 11.4% 6 4.8%. (Figure 2) Of the 5 patients
that developed aGVHD grade 4, 2 died and the re-
maining 3 recovered. However, 1 patient died of sub-
sequent pneumonia 1.5 years after transplantation.
One of the surviving 2 patients remained free of
GVHD through the last follow-up of 904 days after
transplantation, and the other 1 developed limited
cGVHD at 484 days after transplantation and recov-
ered 2 months later. Fifty-two patients that survived
longer than 100 days after transplantation were evalu-
ated for cGVHD. Of 29 patients that had no cGVHD,
21 survived without relapse. Of 14 patients that devel-
oped limited cGVHD, 11 survived. Of 9 patients that
developed extensive cGVHD, 7 survived. The cumula-
tive incidence of cGVHDwas 45.6%6 7.8%, and that
Figure 3. LFS in different risk groups after haploidentical HSCT for
children.
Figure 2. Cumulative incidence of cGVHD after haploidentical stem
cell transplantation for children.
Figure 4. Leukemia-free survival with different diagnosis after haploi-
dentical HSCT for children.
Biol Blood Marrow Transplant 15:91-94, 2009 93Hapliodentical HSCT fir Treatment of Hematologic Malignancies in Childrenof extensive cGVHD was 19.6% 6 6.5% (Figure 2).
The development of aGVHD grade 3-4, and extensive
cGVHD was not associated with the age or gender of
the patients or donors, numbers of MNC, CD31,
CD341 cells infused at transplantation, the extent of
HLA disparity, or the stage of disease before trans-
plantation.
Nineteen opportunistic infections were observed
within the follow-up time. The causes of opportunistic
infection were pneumonia (12 cases), varicella zoster
virus (VZV) (3 cases), bacteremia (2 cases), infection
in the gastrointestinal tract (2 case), and infection in
the central nervous system (1 case). The causes of
pneumonia were CMV in 7 cases, fungi in 1 case, bac-
teria in 1 case, and idiopathic interstitial pneumonia in
3 cases. CMV antigenemia was detected in 24 patients;
however, only 7 case of interstitial pneumonia (IP) was
associated with CMV. Epstein-Barr virus (EBV) anti-
genemia was detected in 2 children, and 1 of these
died of EBV-associated lymphoproliferative disorder.
Hemorrhagic cystitis developed in 9 children at 15 to
160 (median 40) days after transplantation, and lasted
for 2 to 6 (median 3.5) weeks. Seizures occurred in 5
cases within 2 months after transplantation.
At 3 months after transplantation for 5 children
without GVHD, the median CD41 and CD81 cell
counts were 149 and 310 cells/mL, respectively. At 1
year, data were only obtained in 3 children and
CD41 and CD81 cell counts were 382 and 1066
cells/mL, respectively.
Up to August 1, 2008, 40 patients survived. Thirty-
five were free of leukemia. Fourteen of the 35 patients
were classified as high-risk candidates before trans-
plantation with a 22.6% 6 16.7% probability of
LFS. The 3-year probability of LFS for all patients
was 44.7% 6 13.9%. The quality of life of the survi-
vors was evaluated with the Lansky Play performancescale. Six patients who scored 70% were under treat-
ment for extensive GVHD. Of 3 patients who scored
80%, 2 developed cGVHD. Sixteen patients scored
90% and 15 patients scored 100%. Eighteen patients
died. Eight patients died from relapse of leukemia at
a median of 340 (120-706) days after HSCT. Five pa-
tients died from infection: 3 from pneumonia on day
184, 300 and 463, 1 from cytomegalovirus interstitial
pneumonia on day 68, and 1 from cerebral fungal in-
fection on day 170. Two patients died from heart
failure on days 40 and 184; both had received chemo-
therapy before transplantation for 2 and 4 years, re-
spectively. One died from severe aGVHD on day 67;
1 died of infection associated with extensive cGVHD
at 4 years after transplantation. Another died from
EBV-associated lymphoproliferative disorder on day
55. The transplantation-related mortality (TRM) was
8.6% 6 3.7% at 100 days, 14.3% 6 4.7% at 1 year,
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All 13 of the patients that relapsed after HSCT were
diagnosed with ALL before transplantation, and 10
were from the high-risk group. The probability of re-
lapse for high-risk patients was 44.6% 6 10.8% and
that for standard-risk patients was 11.3% 6 6.1% at
2 years after transplantation. Three patients with he-
matologic relapse and 2 with relapse in central nervous
system received chemotherapy or radiotherapy fol-
lowed by donor lymphocyte infusion. These 5 patients
achieved remission and survived free of relapse with
the follow-up 438, 452, 486, 1200, and 1247 days, re-
spectively. The diagnosis of ALL was associated with
a lower probability of LFS (P 5 .004) and a higher
probability of relapse (P 5 .008) after transplantation.The occurrence of cGVHD was associated with
a lower rate of relapse after transplantation (P5 .019).CONCLUSION
The results encourage extending haploidentical
HSCT without ex vivo T cell depletion treatments
to children with an indication for transplantation.ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
disclose.
